Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Brain Neoplasms 2Respiratory Tract Diseases 1Neoplasms 1Meningeal Carcinomatosis 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × AZD3759 × Clear all
NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed
492 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT02228369 2021-01-05

BLOOM

AstraZeneca

Phase 1 Completed
108 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡